ENVISION Phase 3 Study

  • FLASCO
  • March 2, 2018

Evaluating the effect of givosiran (ALN-AS1) on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).

Trial Status: Enrolling

Interested in learning more? Please email us at [email protected]

For more info: ClinicalTrials.gov – NCT03338816

© 2021 FLASCO | Premium Website Design by The HDG

FLASCO